Company logo

BCYC - Bicycle Therapeutics plc

NASDAQ -> Healthcare -> Biotechnology
Cambridge, United Kingdom
Type: Equity

BCYC price evolution
BCYC
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Current assets
Cash $961.36 $457 $526.42 $572.09
Short term investments
Net receivables $46.68 $39.06 $24.04 $17.28
Inventory
Total current assets $1028.26 $515.96 $561.87 $603.04
Long term investments
Property, plant & equipment $22.52 $24.81 $27.68 $30.2
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $1057.36 $547.14 $595.34 $638.68
Current liabilities
Accounts payable $7.45 $7.06 $13.05 $8.49
Deferred revenue
Short long term debt $27.5 $4.97 $4.88 $4.66
Total current liabilities $69.61 $49.51 $69.54 $69.74
Long term debt $8.5 $30.8 $30.7 $30.6
Total noncurrent liabilities
Total debt
Total liabilities $183.54 $191.1 $224.41 $222.66
Shareholders' equity
Retained earnings -$578.14 -$538.32 -$511.76 -$462.66
Other shareholder equity -$1.09 -$0.78 -$1.3 $2.88
Total shareholder equity $873.81 $356.05 $370.93 $416.02
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $526.42 $339.15 $438.68 $135.99
Short term investments
Net receivables $24.04 $21.21 $11.91 $14.63
Inventory
Total current assets $561.87 $369.38 $458.56 $155.72
Long term investments
Property, plant & equipment $27.68 $32.77 $17.79 $3.61
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $595.34 $410.61 $479.79 $161.15
Current liabilities
Accounts payable $13.05 $6.47 $2.72 $1.36
Deferred revenue
Short long term debt $4.88 $3.12 $2.38
Total current liabilities $69.54 $53.34 $36.24 $23.13
Long term debt $30.7 $30.32 $29.87 $14.51
Total noncurrent liabilities
Total debt
Total liabilities $224.41 $139.83 $133.54 $65.69
Shareholders' equity
Retained earnings -$511.76 -$331.1 -$218.38 -$151.56
Other shareholder equity -$1.3 $0.39 -$3.39 -$3.19
Total shareholder equity $370.93 $270.78 $346.25 $95.46
(in millions $) 30 Jun 2024 31 Mar 2024 31 Jan 2024 30 Sep 2023
Revenue
Total revenue $9.36 $19.53 $5.33 $5.35
Cost of revenue $38.3 $38.17
Gross Profit -$28.94 $19.53 -$32.82
Operating activities
Research & development $47.37 $34.86 $45.13
Selling, general & administrative $17.71 $16.38 $17.98
Total operating expenses $56.01 $51.25 $59.75 $56.15
Operating income -$46.65 -$31.72 -$50.8
Income from continuing operations
EBIT
Income tax expense $0.12 -$0.35 $0.32 $2.27
Interest expense -$0.82 -$0.82 $5.64 -$0.81
Net income
Net income -$39.81 -$26.56 -$49.1 -$49.9
Income (for common shares) -$39.81 -$26.56 -$49.9
(in millions $) 31 Dec 2023 31 Jan 2023 31 Jan 2022 31 Jan 2021
Revenue
Total revenue $26.98
Cost of revenue $156.5
Gross Profit -$129.52
Operating activities
Research & development $180.96
Selling, general & administrative $60.43
Total operating expenses $216.92
Operating income -$189.95
Income from continuing operations
EBIT
Income tax expense $1.46
Interest expense -$3.26
Net income
Net income -$180.66
Income (for common shares) -$180.66
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Net income -$39.81 -$26.56 -$49.1 -$49.9
Operating activities
Depreciation $1.64 $1.66 $1.65 $1.69
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$44.63 -$70.87 -$47.29 -$1.02
Investing activities
Capital expenditures -$0.42 -$0.01 -$0.05 -$0.5
Investments
Total cash flows from investing -$0.42 -$0.01 -$0.05 -$0.5
Financing activities
Dividends paid
Sale and purchase of stock $549.61 $1.87 $234.63
Net borrowings
Total cash flows from financing $549.61 $1.87 $0.39 $234.63
Effect of exchange rate
Change in cash and equivalents $504.37 -$69.43 -$45.66 $232.2
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$180.66 -$112.72 -$66.82 -$51.01
Operating activities
Depreciation $6.55 $3.69 $1.41 $1.28
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$60.63 -$86.11 -$14.79 -$17.79
Investing activities
Capital expenditures -$18.99 -$2.03 -$1.2
Investments
Total cash flows from investing -$2.93 -$18.99 -$2.03 -$1.2
Financing activities
Dividends paid
Sale and purchase of stock $250.03 $6.69 $305.73 $48.42
Net borrowings $15 $15
Total cash flows from financing $250.03 $6.69 $320.73 $62.84
Effect of exchange rate -$1.21 $0.02
Change in cash and equivalents $187.82 -$99.53 $302.69 $43.87
Fundamentals
Market cap $2.16B
Enterprise value N/A
Shares outstanding 91.33M
Revenue $39.57M
EBITDA N/A
EBIT N/A
Net Income -$165.37M
Revenue Q/Q -17.89%
Revenue Y/Y 75.71%
P/E ratio -13.03
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 54.47
P/B ratio 2.46
Book/Share 9.58
Cash/Share 10.53
EPS -$1.81
ROA -23.30%
ROE -32.80%
Debt/Equity 0.60
Net debt/EBITDA N/A
Current ratio 14.77
Quick ratio N/A